These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 28110399)

  • 1. Safinamide: A Review in Parkinson's Disease.
    Blair HA; Dhillon S
    CNS Drugs; 2017 Feb; 31(2):169-176. PubMed ID: 28110399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
    Hattori N; Tsuboi Y; Yamamoto A; Sasagawa Y; Nomoto M;
    Parkinsonism Relat Disord; 2020 Jun; 75():17-23. PubMed ID: 32446176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients.
    Cattaneo C; Jost WH; Bonizzoni E
    J Parkinsons Dis; 2020; 10(1):89-97. PubMed ID: 31594253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
    Kurihara K; Mishima T; Fujioka S; Tsuboi Y
    Expert Opin Drug Saf; 2022 Feb; 21(2):137-147. PubMed ID: 34597253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease.
    Abbruzzese G; Barone P; Lopiano L; Stocchi F
    Drug Des Devel Ther; 2021; 15():2507-2517. PubMed ID: 34140766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.
    Fabbri M; Rosa MM; Abreu D; Ferreira JJ
    Neurodegener Dis Manag; 2015 Dec; 5(6):481-96. PubMed ID: 26587996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
    Perez-Lloret S; Rascol O
    Expert Rev Neurother; 2016; 16(3):245-58. PubMed ID: 26849427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):693-699. PubMed ID: 28537214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safinamide for the treatment of Parkinson's disease.
    deSouza RM; Schapira A
    Expert Opin Pharmacother; 2017 Jun; 18(9):937-943. PubMed ID: 28504022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
    Cattaneo C; Ferla RL; Bonizzoni E; Sardina M
    J Parkinsons Dis; 2015; 5(3):475-81. PubMed ID: 26406127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effectiveness and safety of safinamide as add-on to levodopa in patients with parkinson's disease: non-interventional study].
    Jost WH; Kupsch A; Mengs J; Delf M; Bosse D
    Fortschr Neurol Psychiatr; 2018 Oct; 86(10):624-634. PubMed ID: 30142650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safinamide for the treatment of Parkinson's disease.
    Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt MH; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Sep; 29(10):1273-80. PubMed ID: 25044402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall Efficacy and Safety of Safinamide in Parkinson's Disease: A Systematic Review and a Meta-analysis.
    Giossi R; Carrara F; Mazzari M; Lo Re F; Senatore M; Schicchi A; Corrù F; Fittipaldo VA; Pani A; Tramacere I; Elia AE; Scaglione F
    Clin Drug Investig; 2021 Apr; 41(4):321-339. PubMed ID: 33674954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safinamide: first global approval.
    Deeks ED
    Drugs; 2015 Apr; 75(6):705-11. PubMed ID: 25851099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease.
    Schapira AH; Stocchi F; Borgohain R; Onofrj M; Bhatt M; Lorenzana P; Lucini V; Giuliani R; Anand R;
    Eur J Neurol; 2013 Feb; 20(2):271-80. PubMed ID: 22967035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real life evaluation of safinamide effectiveness in Parkinson's disease.
    Mancini F; Di Fonzo A; Lazzeri G; Borellini L; Silani V; Lacerenza M; Comi C
    Neurol Sci; 2018 Apr; 39(4):733-739. PubMed ID: 29441484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt M; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Feb; 29(2):229-37. PubMed ID: 24323641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safinamide effect on sleep architecture of motor fluctuating Parkinson's disease patients: A polysomnographic rasagiline-controlled study.
    Bovenzi R; Conti M; Pierantozzi M; Testone G; Fernandes M; Manfredi N; Schirinzi T; Cerroni R; Mercuri NB; Stefani A; Liguori C
    Parkinsonism Relat Disord; 2024 Oct; 127():107103. PubMed ID: 39154406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.